We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.
- Authors
Luizon, M R; Palei, A C T; Sandrim, V C; Amaral, L M; Machado, J S R; Lacchini, R; Cavalli, R C; Duarte, G; Tanus-Santos, J E
- Abstract
Tissue inhibitor of metalloproteinase (TIMP)-1 is a major endogenous inhibitor of matrix metalloproteinase (MMP)-9, which may affect the responsiveness to therapy in hypertensive disorders of pregnancy. We examined whether TIMP-1 polymorphism (g.-9830T>G, rs2070584) modifies plasma MMP-9 and TIMP-1 levels and the response to antihypertensive therapy in 596 pregnant: 206 patients with preeclampsia (PE), 183 patients with gestational hypertension (GH) and 207 healthy pregnant controls. We also studied the TIMP-3 polymorphism (g.-1296T>C, rs9619311). Plasma MMP-9 and TIMP-1 levels were measured by ELISA. GH patients with the GG genotype for the TIMP-1 polymorphism had lower MMP-9 levels and MMP-9/TIMP-1 ratios than those with the TT genotype. PE patients with the TG genotype had higher TIMP-1 levels. The G allele and the GG genotype were associated with PE and responsiveness to antihypertensive therapy in PE, but not in GH. Our results suggest that the TIMP-1 g.-9830T>G polymorphism not only promotes PE but also decreases the responses to antihypertensive therapy.
- Subjects
TISSUE inhibitors of metalloproteinases; ANTIHYPERTENSIVE agents; HYPERTENSION in pregnancy; GENETIC polymorphisms; PREECLAMPSIA; THERAPEUTICS
- Publication
Pharmacogenomics Journal, 2014, Vol 14, Issue 6, p535
- ISSN
1470-269X
- Publication type
Article
- DOI
10.1038/tpj.2014.26